T cell factor (Tcf) proteins bind ␤-catenin and are downstream effectors of Wnt/␤-catenin signals. A recently demonstrated interaction between ␤-catenin and the androgen receptor (AR) ligand binding domain has suggested that AR may be a Tcf-independent Wnt/␤-catenin effector. This study demonstrates that there is a direct interaction between the AR DNA binding domain (DBD) and Tcf4. Tcf4 bound specifically to a glutathione S-transferase-ARDBD fusion protein and could be coimmunoprecipitated with ␤-catenin and transfected AR or endogenous AR in prostate cancer cells. Transfected Tcf4 repressed the transcriptional activity of full-length AR and a VP16-ARDBD fusion protein, and this repression was only partially reversed by transfected ␤-catenin. AR activation by cyproterone acetate, a partial agonist that did not support ␤-catenin binding to the AR, was also repressed by Tcf4, further indicating that repression was not due to ␤-catenin sequestration. Tcf4 could recruit ␤-catenin to the AR DBD in vitro and to the cyproterone acetate-liganded AR in vivo. Chromatin immunoprecipitation experiments in LNCaP prostate cancer cells showed that endogenous AR was bound to a Tcf4-responsive element in the c-myc promoter. These findings indicate that AR and Tcf4 can interact directly and that this interaction may occur on the promoters or enhancers of particular genes. The direct AR-Tcf4 interaction, in conjunction AR-and Tcf4-␤-catenin binding, provides a mechanism for cooperative and selective gene regulation by AR and the Wnt/␤-catenin-Tcf pathway that may contribute to normal and neoplastic prostate growth.
The androgen receptor (AR) 1 is a steroid hormone receptor member of the larger nuclear receptor superfamily and plays a central role in normal male development and prostate cancer (1, 2) . It contains a highly conserved central DNA binding domain (DBD), a C-terminal ligand binding domain (LBD), and a large N-terminal transactivation domain. AR activation by androgen binding causes a conformational change that enhances nuclear localization, homodimerization, and binding to specific sequences (androgen-responsive elements, AREs) located in androgen-regulated genes. The androgen-induced conformational change in the AR LBD also generates a binding site for a short hydrophobic motif (Leu-X-X-Leu-Leu or LXXLL) found in many transcriptional coactivator proteins, although the AR N terminus contains an LXXLL-like sequence that binds strongly to the liganded LBD and may compete for binding with other LXXLL-containing coactivators (3) . Similarly to other steroid hormone and nuclear receptors, protein-protein interactions involving one or more domains of the AR mediate the recruitment of multiple transcription factors, with subsequent chromatin remodeling and transcription of androgen regulated genes (4) .
The binding of AR and other steroid hormone receptors to DNA can be enhanced by HMG-1 and HMG-2, related nonsequence-specific DNA binding proteins characterized by a high mobility group (HMG) box DBD (5) (6) (7) (8) (9) (10) . HMG box-containing proteins have an architectural function based on the ability of the HMG box to bind to the minor groove of the DNA helix and induce a sharp bend. This change in local DNA structure appears to be the major factor responsible for HMG-1 and -2 stabilization of steroid hormone receptor binding to DNA, although weak protein-protein interactions may also play a role. We recently demonstrated an interaction between the AR and the sequence-specific HMG box transcription factor SRY, the Y-chromosome encoded protein required for male sex determination and founding member of the SOX family of HMG proteins (11) . The AR-SRY interaction was direct and mediated by the AR DBD and the HMG domain of SRY. Based on this finding, we have investigated whether the AR can interact directly with other HMG proteins. This study demonstrates such an interaction between the AR and T cell factor 4 (Tcf4), a member of the Tcf/Lef (T cell factor/lymphoid enhancer factor) family that is expressed in multiple tissues, including colon, breast, and prostate (12) (13) (14) (15) (16) (17) .
Tcf4 and the other human Tcf proteins (Tcf1, Tcf2/Lef1, and Tcf3) are sequence-specific HMG box transcription factors that function as the downstream effectors of Wnt/␤-catenin signals (17) (18) (19) (20) (21) (22) (23) (24) (25) . In the absence of nuclear ␤-catenin, the Tcf proteins strongly repress transcription through binding of the Groucho family of transcriptional corepressors (in humans termed transducin-like enhancers of split, TLE) (15, 26 -29) . Binding is mediated by a conserved N-terminal glutamine-rich region in the Groucho/TLE proteins and a region between the N-terminal ␤-catenin binding site and HMG box in the Tcf proteins. Stabilization of ␤-catenin by Wnt or other signals results in its nuclear accumulation and Tcf binding, mediated by sites in the Tcf N terminus and ␤-catenin Armadillo repeats (30 -32) . ␤-Catenin then serves to stimulate Tcf transcriptional activity by recruiting multiple coactivator proteins such as CBP/p300, Brg1, and CARM1 (24, (33) (34) (35) (36) (37) (38) . Inappropriate stabilization of ␤-catenin through a number of mechanisms has been observed in many cancers, with decreased ␤-catenin degradation due to adenomatous polyposis coli loss being a cause of familial colon cancer (22, 23) .
Recent reports have shown that ␤-catenin can bind to the AR LBD and function as an AR coactivator protein (16, 39 -44) . Direct interactions have also been described between ␤-catenin and retinoic acid and vitamin D receptors (45, 46) . These findings have suggested that AR and other nuclear receptors may be Tcf-independent effectors of Wnt/␤-catenin signaling pathways and may indirectly antagonize Tcf activity by competing for nuclear ␤-catenin. This study demonstrates a direct (␤-catenin-independent) interaction between Tcf4 and the AR mediated by the AR DBD, indicating a role for Tcf4 in Wnt/␤-catenin signaling through the AR. A cooperative binding interaction between AR and Tcf4 on the regulatory elements of particular genes is a mechanism by which Wnt/␤-catenin signals may selectively stimulate expression of a subset of AR-regulated genes during male development and in prostate cancer.
EXPERIMENTAL PROCEDURES
Plasmids and Reagents-A human AR expression vector, pSVARo, was from A. Brinkmann (47) . VP16-ARDBD-(501-660) generated in the pACT vector (Promega, Madison, WI) and the ARE-regulated firefly luciferase reporter genes (ARE 4 -Luc, PSA7kb-Luc, and MMTV-Luc) generated in the pGL3 vector were described previously (11) . An estrogen receptor ␣ (ER␣) expression vector (pcDNA3.1-ER␣) and estrogenresponsive element (ERE)-regulated luciferase reporter (ERE 2 -Luc) were from M. Brown (Dana Farber Cancer Institute, Boston, MA). A human Tcf4 expression vector (pCMV-Tcf4, 597 amino acids) was from S. Sokol (Beth Israel Deaconess, Boston, MA) (22) , and ␤-catenin was from H. Clevers (University Medical Center, Utrecht). Vectors encoding Renilla luciferase (pRL-CMV) and ␤galactosidase (pSV-␤-galactosidase) were from Promega.
GST-ARDBD-(556 -628) and GST-AR-(634 -668) were generated by inserting a PCR-amplified fragment of AR in pGEX-2TK (Amersham Biosciences). The corresponding GST fusion proteins were purified using glutathione-agarose beads (Amersham Biosciences). Mouse antiTcf4 monoclonal antibodies (clone 6H5-3 specific for Tcf4 and clone 6F12-3 recognizing Tcf3 and -4) were from Upstate Biotechnology (Lake Placid, NY) and were used in combination for immunoblotting. Rabbit anti-AR antibodies generated against an N-terminal peptide (N-20) were from Santa Cruz Biotechnology (Santa Cruz, CA) or Upstate Biotechnology (immunoaffinity-purified PG-21). The mouse anti-␤-catenin monoclonal antibody (clone 14) was from BD Biosciences Transduction Laboratories (Lexington, KY). Hormones were from Sigma and were diluted from 1000ϫ stocks in ethanol.
Transient Transfections and Reporter Gene Assays-CV1 cells were cultured in 24-well plates in DMEM with 5% FCS (HyClone, Logan, UT) to ϳ80% confluence. Plasmid DNA and 2 l of LipofectAMINE 2000 (Invitrogen) were combined in a final volume of 100 l of OPTI-MEM for 30 min at room temperature, then mixed with 0.5 ml of DMEM with 10% steroid hormone-depleted FCS (charcoal-dextran-stripped FCS, CS-FCS) (HyClone), and added to each culture well. After 24 h the medium was replaced with 0.5 ml of DMEM/10% CS-FCS, with or without hormones as indicated. After another 24 h, the cells were rinsed with PBS, lysed with 100 l of passive lysis buffer, and assayed for luciferase activities using a Dual-Luciferase reporter assay (Promega). The firefly luciferase results were divided by the control Renilla luciferase to give relative light units, and the results reflect the mean and standard deviation from triplicate samples.
GST Fusion Protein Binding Assays-Equivalent amounts (5 g) of GST or GST fusion proteins and 35 S-labeled proteins generated by in vitro transcription/translation (TNT T7 or SP6 Quick Coupled Transcription/Translation System, Promega) were mixed in 0.2 ml of binding buffer (PBS, pH 7.4, 1 mM dithiothreitol, 1 mg/ml bovine serum albumin, 0.05% Triton X-100, and protease inhibitors) for 2 h at 4°C. Beads were washed three times in binding buffer, once in PBS, eluted with SDS-PAGE sample buffer, and run on 10% SDS-PAGE gels under reducing conditions.
Coimmunoprecipitations-CV1 or 293T cells grown in 10-cm plates to 80 -90% confluence were transfected with 6 g each of AR and Tcf4 plasmids. DNA in 0.75 ml of OPTI-MEM was mixed with 40 l of LipofectAMINE 2000 in 0.75 ml of OPTI-MEM as above, and the 1.5 ml of mix was added to cells in 10 ml of DMEM/10% FCS with no antibiotics. After 24 h, the medium was replaced with DMEM/10% FCS or CS-FCS with added hormones as indicated. After another 24 h, cells from each plate were washed with cold PBS, scraped into 1.5 ml of immunoprecipitation buffer (PBS, pH 7.4, 10% glycerol, .05% Triton X-100, and protease inhibitors), and briefly sonicated, and debris was removed by centrifugation for 10 min at 12,000 ϫ g. Lysates were precleared for 15 min using 2 l of normal rabbit serum that was pre-absorbed to 20 l of protein A-Sepharose beads. Lysates were then split, mixed with 5 l of protein A-Sepharose beads and 1 g of anti-AR (Santa Cruz N-20) or control normal rabbit serum (1 g of IgG), and rotated for 2 h at 4°C. The beads were then washed three times in immunoprecipitation buffer, washed once in PBS, eluted in SDS-PAGE sample buffer, and run on 10% SDS-PAGE gels under reducing conditions.
LNCaP cells (obtained from the ATCC) were grown in RPMI 1640 with 10% FCS and 10 nM DHT. The LAPC4 prostate cancer cell line (kindly provided by C. Sawyers, University of California at Los Angeles, CA) (48) was grown in Iscove's modified Dulbecco's medium with 10% FCS and 10 nM DHT. Coimmunoprecipitations were carried out under the same conditions as above, or in an alternative buffer containing 0.5% Triton X-100 and no glycerol where indicated. Proteins were transferred to nitrocellulose and detected by immunoblotting with the indicated antibodies (1:1000 dilutions incubated overnight at 4°C), followed by horseradish peroxidase-conjugated anti-mouse or rabbit Ig secondaries (Promega) and ECL (Amersham Biosciences).
Chromatin Immunoprecipitation-Plates (10 cm) containing LNCaP cells were cultured for 2 days in RPMI 1640/10% FCS and then 2 days in RPMI-1640/10% CS-FCS, followed by pulsing with DHT (10 nM). Plates were then rinsed with PBS and fixed for 10 min at room temperature with 1% formaldehyde in PBS. After chromatin extraction, shearing, and preclearing steps as described previously (49), samples were split and immunoprecipitated with 500 ng of affinity-purified rabbit anti-AR or control (rabbit anti-PDGF receptor) antibodies (Upstate Biotechnology). The conditions for immunoprecipitations, crosslink reversal, DNA purification, and PCR amplification (using 10% of the sample for each reaction) were as described previously (49) . Primers flanking Tcf4 binding element 1 in the c-myc promoter (CCTTTGATT at Ϫ1001 from the initiation ATG) (50) were GCTCTCCACTTGCCCCTT-TTA (forward) and GTTCCCAATTTCTCAGCC (reverse). Primers flanking the major PSA gene enhancer were TGAGAAACCTGAGATT-AGGA and ATCTCTCTCAGATCCAGGCT, and control primers were in the CD1d gene (49) . PCR amplifications were carried out for 30 cycles, and input reflected 5% of the chromatin samples used for the immunoprecipitations.
RESULTS

AR Binds
Directly to Tcf4 -Previous data demonstrating a protein-protein interaction between AR and SRY that was mediated by their respective zinc finger and HMG box DNA binding domains suggested that AR might interact directly with other HMG box proteins (11) . This hypothesis was tested initially in glutathione S-transferase (GST) fusion protein pulldown experiments using a GST-ARDBD fusion protein and HMG proteins that were 35 S-labeled by in vitro transcription/ translation. One HMG protein examined was T cell factor 4 (Tcf4), a member of the Tcf/Lef family of sequence-specific HMG box proteins that is expressed in multiple epithelial tissues, including prostate (16) . Similarly to SRY, 35 S-labeled Tcf4 bound specifically to a fusion protein containing the AR DBD, GST-ARDBD-(556 -628), and not to GST or an AR hinge region fusion protein, GST-AR-(634 -668) (Fig. 1A) . It should be noted that the in vitro transcribed/translated Tcf4 migrated as two bands with the upper band being ϳ68 kDa, consistent with the predicted size of the unmodified protein. The lower band, which also bound to the GST-ARDBD-(556 -628) protein, may be a proteolytic product or internally initiated protein.
Significantly, GST-ARDBD-(556 -628) did not bind to ␤-cate-nin, consistent with previous reports showing that ␤-catenin binds to the AR LBD (39 -44) (Fig. 1A ). This result indicated that the Tcf4 binding was direct and not mediated by ␤-catenin. Another control protein, ␤-galactosidase, similarly failed to bind any of the GST proteins.
Coimmunoprecipitation experiments then addressed whether there was a detectable interaction between intact AR and Tcf4 in vivo. CV1 cells (which do not express endogenous AR) were transiently transfected with AR and Tcf4 expression vectors and treated for 24 h with or without androgen (5␣-dihydrotestosterone (DHT)), and lysates were immunoprecipitated with an anti-AR or control antibodies. Interestingly, anti-Tcf4 immunoblotting of the input lanes showed primarily a band at ϳ86 kDa and a much weaker band at the expected size of 68 kDa (Fig. 1B) . The same major 86-kDa band was detected by two different anti-Tcf4 antibodies and was not found in the nontransfected cells (data not shown). A larger Tcf4 isoform of ϳ86 kDa has also been found in prostate cancer cell lines and may be due to attachment of SUMO as has been described for Tcf2/Lef1 (16, 51) .
In any case, both Tcf4 isoforms were coprecipitated by the anti-AR antibody in the lysate from AR-and Tcf4-cotransfected cells treated with DHT (Fig. 1B) . In contrast, minimal Tcf4 was found in the control nonimmune antibody precipitates or in the anti-AR precipitate from cells that were transfected only with Tcf4. The Tcf4 coimmunoprecipitation was also markedly diminished in the absence of DHT, further indicating that it was mediated by the AR. It should be noted that this latter result does not imply a strict androgen dependence for Tcf4 binding but may reflect stabilization of AR-Tcf4 binding by ␤-catenin (see below).
Tcf4 Represses AR Transcriptional Activity in Transient Transfections-Transient transfections with AR, Tcf4, and an AR-regulated reporter gene were carried out to determine whether there were functional interactions between intact AR and Tcf4. CV1 cells cotransfected with an AR expression vector and an AR-regulated firefly luciferase reporter gene (ARE 4 -Luc) showed strong DHT-dependent transcriptional activity ( Fig. 2A) . Cotransfection with a Tcf4 expression vector resulted in a marked and dose-dependent decrease in luciferase activity ( Fig. 2A) . Interestingly, the repression was somewhat less at the highest levels of Tcf4 (100 -200 ng), possibly reflecting sequestration of a corepressor. The repression was specific, because activity of a cotransfected Renilla luciferase reporter gene regulated by a CMV promoter was not decreased (Fig. 2B) . Anti-AR immunoblots of the same lysates used for the luciferase assays further indicated that repression, which was Ͼ50% at 5 ng of Tcf4 plasmid, was not due to decreased AR expression (Fig. 2C) . These findings were consistent with recent reports that also found Tcf4 inhibition of AR in transient transfections (43, 44) .
Additional AR-regulated reporter genes were analyzed to determine whether the Tcf4 repression was general versus enhancer-specific. Tcf4 markedly repressed AR transcriptional activity on a reporter gene regulated by an androgendependent prostate-specific antigen (PSA) promoter/enhancer (PSA7kb-Luc), containing 7 kb upstream of the PSA coding region with multiple AREs (Fig. 3A) . Tcf4 similarly repressed AR activity on an MMTV-LTR reporter (MMTVLuc), containing two AREs (Fig. 3B) . Repression of the ARE 4 -Luc reporter by Tcf4 was also observed in another cell line, human 293T cells (data not shown). These results indicated that repression was not reporter gene-or cell type-dependent.
A previous report indicated that Tcf4 could interact directly with ER␣ and inhibit its transcriptional activity (52) . Therefore, the effects of Tcf4 on AR and ER␣ transcriptional activity were compared. In contrast to the results with AR, Tcf4 did not repress ER␣ in transfected CV1 cells (Fig. 3C) . The ER␣ was also largely unaffected by cotransfection with ␤-catenin under conditions that could markedly stimulate AR activity, consistent with a previous report showing that ER␣ was not stimulated by ␤-catenin (Fig. 3D and below) (40) . These results further indicated that the repression of AR by Tcf4 was not a general effect on transcription and suggested that distinct factors or mechanisms may govern Tcf4 interactions with AR versus ER␣.
Tcf4 Repression of AR Activity Is Independent of ␤-Catenin-As shown previously by several groups, ␤-catenin can enhance DHT-dependent AR transcriptional activity through an interaction with the AR LBD (Fig. 4A) (16, 39 -44 ). Therefore, it was possible that Tcf4 repression of AR transcriptional activity reflected sequestration of ␤-catenin, rather than a direct AR-Tcf4 interaction. Consistent with this mechanism, cotransfection of ␤-catenin could augment DHT-stimulated AR transcriptional activity in the presence of Tcf4 (Fig. 4B) . How- ever, the Tcf4-mediated repression of AR activity was only partially reversed by ␤-catenin, despite transfection with amounts of ␤-catenin that could markedly enhance AR activity in the absence of transfected Tcf4 (Fig. 4, compare A and B) . This suggested that repression of AR activity was not due solely to sequestration of ␤-catenin.
To confirm that the repression by Tcf4 reflected a direct interaction with the AR DBD and was not due to effects on AR-␤-catenin interactions, the AR DBD was examined directly. For this purpose, the AR DBD (amino acids 501-660) was fused to the heterologous VP16 transactivation domain, deleting both the AR N terminus and LBD. The VP16-ARDBD-(501-660) fusion protein could strongly transactivate the ARE 4 -Luc reporter, and, consistent with deletion of the AR LBD, this activity was androgen-independent (Fig. 4C) . Similarly to fulllength AR, VP16-ARDBD-(501-660) could be strongly repressed by Tcf4 (Fig. 4C ). This result indicated that Tcf4 repression of AR transcriptional activity was not due to an effect on AR-␤-catenin binding and supported the conclusion that it was mediated by an interaction with the AR DBD.
Tcf4 Repression of the Cyproterone Acetate-liganded AR in the Absence of Coativation by ␤-Catenin-Although the above data indicated that Tcf4 could bind to the AR DBD and repress a VP16-ARDBD fusion protein, its direct (␤-catenin-independent) effects on full-length wild-type AR were still uncertain. Therefore, a further approach to assess effects of Tcf4 that were independent of the AR-␤-catenin interaction was to identify an AR partial agonist that did not support the AR-␤-catenin interaction. One candidate was cyproterone acetate (CPA), a drug used as an AR antagonist for the treatment of prostate cancer that can nonetheless stimulate AR transcriptional activity in transient transfection assays. In CV1 cells transfected with AR and an ARE 4 -Luc reporter, CPA (1 M) was ϳ50% as active as DHT (10 nM) in stimulating the AR in the absence of transfected ␤-catenin (Fig. 5, A and B) . However, in contrast to the DHT-liganded AR that was strongly stimulated by ␤-catenin (Fig. 5A) , the CPA-liganded AR was not stimulated and was instead repressed by ␤-catenin (Fig. 5B) . This repression may reflect sequestration of critical coactivator proteins such as CBP or CARM1. A very recent study similarly found that ␤-catenin did not coactivate the CPA-liganded AR (44) .
Based on these results, CPA was used to assess ␤-cateninindependent effects of Tcf4 on the full-length wild-type AR. Similarly to the results with DHT ( Fig. 5C and above) , the CPA-liganded AR was markedly repressed by Tcf4 (Fig. 5D ). In conjunction with the above data, this result indicated that Tcf4 could interact with the AR independent of the AR interaction with ␤-catenin.
Tcf4 Can Recruit ␤-Catenin to the AR-The site on Tcf4 that binds ␤-catenin is located at the N terminus (amino acids 1-55), whereas the HMG domain is located toward the C terminus (amino acids 327-401). This suggested that Tcf4 might be able to simultaneously bind ␤-catenin and AR, thereby enhancing ␤-catenin recruitment to the AR. This hypothesis was first tested in vitro by assessing ␤-catenin binding to an AR DBD fusion protein, GST-ARDBD-(556 -628), in the absence or presence of Tcf4. As shown above, Tcf4 could bind strongly to the AR DBD, whereas there was no detectable direct binding of ␤-catenin (Fig. 6A) . In contrast, substantial ␤-catenin binding was observed when ␤-catenin and Tcf4 were coincubated with the GST-ARDBD-(556 -628) fusion protein, indicating that Tcf4 could recruit ␤-catenin to the AR in vitro (Fig. 6A ).
Coimmunoprecipitations were next carried out to determine whether Tcf4 could recruit ␤-catenin to the full-length AR in vivo. Specifically, because ␤-catenin was shown previously to associate with the DHT-liganded AR, it was determined whether transfected Tcf4 could induce ␤-catenin binding to the CPA-liganded AR. Cells were cotransfected with AR and Tcf4 and then cultured for 24 h with DHT or CPA. Lysates were then immunoprecipitated with an anti-AR or control antibody, and coimmunoprecipitated proteins were detected by immunoblotting. Both Tcf4 and ␤-catenin were readily detected in the anti-AR immunoprecipitates from the DHT-treated cells transfected with AR and Tcf4 (Fig. 6, B and C, respectively) . In contrast, there was no specific coimmunoprecipitation of Tcf4 or ␤-catenin from the CPA-treated cells. This was not due to decreased levels of Tcf4, ␤-catenin, or AR in the lysates, because these were comparable in the DHT-and CPA-treated cells (Fig. 6, B and C, and data not shown). This result indicated that Tcf4 was not able to directly mediate ␤-catenin binding to the AR that was stable enough to be detected by coimmunoprecipitation. Moreover, the failure to coimmunoprecipitate AR and Tcf4 from the CPA-treated cells indicated that the in vivo binding of Tcf4 to the DHT-liganded AR was likely stabilized by ␤-catenin.
Although a stable interaction between the CPA-liganded AR, Tcf4, and ␤-catenin could not be readily detected by coimmunoprecipitation, this did not rule out a physiologically significant in vivo interaction. Therefore, a more sensitive functional assay was used to determine whether Tcf4 could recruit ␤-catenin to the AR independently of the ␤-catenin interaction with the DHT-liganded AR LBD. CV1 cells were transfected with AR and ␤-catenin, plus or minus Tcf4, and were then stimulated with CPA. As shown above, ␤-catenin failed to enhance the transcriptional activity of the CPA-liganded AR (Fig. 7A) . In contrast, ␤-catenin could markedly enhance the CPA-liganded AR when it was cotransfected with Tcf4 (Fig. 7B) . This result was consistent with the in vitro GST pull-down results and indicated that Tcf4 could mediate recruitment of ␤-catenin to the AR in vivo.
Interaction between Endogenous AR and Tcf4 in Prostate Cancer Cells-Coimmunoprecipitations from LNCaP and LAPC4 prostate cancer cells were next carried out to determine whether endogenous AR⅐Tcf4⅐␤-catenin complexes could be detected. Both cell lines express endogenous AR (with a ligand binding domain mutation in LNCaP) and Tcf4, with higher Tcf4 levels in LAPC4 (43) . As shown previously (39), endogenous AR and ␤-catenin could be coimmunoprecipitated from androgen-stimulated LNCaP cells and be similarly coimmunoprecipitated from LAPC4 cells (Fig. 8A) . However, the amount of ␤-catenin that could be coimmunoprecipitated with AR was extremely low, and a specific coimmunoprecipitated Tcf4 band was not detectable in the LNCaP cells (data not shown). In contrast, Tcf4 could be detected specifically in anti-AR immunoprecipitates from LAPC4 cells (Fig. 8B) . Consistent with the results in AR-and Tcf4-transfected cells (Fig. 7) , the coimmunoprecipitation was observed in DHT-treated cells but not in the absence of androgen or in CPA-treated cells.
Chromatin immunoprecipitations were carried out to further assess the functional significance of the AR interaction with Tcf4 and to specifically test the hypothesis that AR can associate with Tcf4 on the promoters of Tcf4-regulated genes. A number of Tcf4-regulated genes have been reported, including c-myc, and specific sequences mediating Tcf4 binding to the c-myc promoter (Tcf4 binding elements) have been identified (50) . Therefore, PCR primers flanking one of the two Tcf4 binding elements in the c-myc promoter were used to assess AR binding. Chromatin was isolated from formalin-treated LNCaP cells, sheared by sonication, immunoprecipitated by anti-AR or control antibodies, heated to reverse formalin cross-links, and PCR-amplified by a series of primers (Fig. 9) . As a positive control, PCR amplification with primers flanking the major ARE in the PSA gene enhancer demonstrated DHT-dependent association of the AR with this enhancer. Primers flanking the c-myc Tcf4 binding element similarly detected this element in the anti-AR immunoprecipitate, with a marked increase in the DHT-stimulated cells. Negative controls included PCR amplification of the same DNA with irrelevant primers and immunoprecipitation with an irrelevant rabbit antibody. In conjunction with the above studies, these results support the conclusion that there is a physiological interaction between endogenous AR and Tcf4. tivator (17, 19 -25) . However, although several Wnt/␤-cateninTcf-regulated genes such as cyclin D1 and c-myc have been identified, the spectrum of genes directly targeted by this pathway in particular tissues and developmental stages remains to be determined (50, 53, 54) . Recent data showing that ␤-catenin could also function as a transcriptional coactivator for the AR through an interaction with the AR LBD have indicated that AR might be a Tcf-independent effector of the Wnt/␤-catenin pathway (16, 39 -44) . This study demonstrates that Tcf4, a Tcf/Lef protein expressed in multiple tissues, including prostate cancer cell lines, can interact directly with the AR. This indicates that the AR, rather than being a Tcf-independent target of Wnt/␤-catenin signaling, may instead function cooperatively with Tcf4 to regulate the expression of particular genes in response to Wnt/␤-catenin signals.
Tcf4 was shown through in vitro GST pull-down and in vivo functional assays to directly interact with the AR DBD, independently of the ␤-catenin interaction with the AR LBD. Moreover, Tcf4 could recruit ␤-catenin to the AR in the absence of an interaction between ␤-catenin and the AR LBD. However, a stable interaction between the full-length AR and Tcf4 (as assessed by coimmunoprecipitation) was agonist (DHT)-dependent, indicating a likely role for ␤-catenin in stabilizing the AR-Tcf4 binding interaction. An additional factor that may of course stabilize the AR-Tcf4 interaction in vivo is DNA binding, particularly in the case of genes that contain binding sites for both AR and Tcf4. Indeed, it is possible that the AR-Tcf4 interaction is physiologically significant primarily in the context of genes containing cis-elements that mediate specific binding of both AR and Tcf4. This hypothesis is supported by the chromatin immunoprecipitation data showing that AR associates with Tcf4 binding sites on the c-myc promoter, although it is not yet clear whether there are AR binding ciselements (possibly weak nonconsensus elements) in the c-myc gene that contribute to the association.
Tcf4 was found to repress AR transcriptional activity in transient transfections, consistent with other recently reported data (43, 44) . This repression was not solely due to a decrease in ␤-catenin coactivator activity, because it was observed under conditions in which ␤-catenin did not have coactivator function, and it was only partially reversed by cotransfection with ␤-catenin. Tcf/Lef proteins have been shown to repress transcription through recruitment of Groucho/TLE corepressor proteins and for some forms through recruitment of CtBP (15, (27) (28) (29) 55) . Significantly, a previous study found that a human Groucho/TLE protein, amino-terminal enhancer of split, could bind via its conserved glutamine-rich domain to the AR N terminus and repress AR transcriptional activity (56) . This suggests that the potent AR corepressor activity of transfected Tcf4 may be due to its ability to enhance the binding of Groucho/TLE proteins to the AR. It should be noted that displacement of Groucho/TLE by ␤-catenin has been suggested as a mechanism that may contribute to transcriptional activation of Tcf/Lef proteins by ␤-catenin, although the proteins bind to distinct sites on Tcf/Lef and direct evidence for this model is lacking (17) . In any case, the limited ability of ␤-catenin to reverse AR repression by Tcf4 observed here indicates that ␤-catenin does not readily displace a corepressor, possibly due to the formation of a very stable AR⅐Tcf4⅐Groucho/TLE complex.
A further finding in this study was that ␤-catenin did not interact with the CPA-liganded AR. CPA is a partial agonist of the AR that has been widely used for the treatment of prostate cancer, but the molecular basis for its ability to suppress prostate cancer growth has not been clear (57) . In contrast to the selective estrogen receptor modulators used in breast cancer (such as tamoxifen), which function as relatively pure estrogen receptor antagonists in mammary epithelium-derived cells, CPA can strongly stimulate AR transcriptional activity in LNCaP prostate cancer cells. An insight into the mechanism of action of CPA (and several other AR partial agonists) was the finding that the interaction between the AR N terminus and LBD did not occur with the CPA-liganded AR, indicating that the DHT-and CPA-liganded AR LBDs assumed distinct con- formations (58) . The results of this study indicate that loss of ␤-catenin binding by the CPA-liganded AR LBD may be a factor contributing to the ability of CPA to selectively suppress prostate cancer growth. Importantly, if this is correct it would provide a molecular target for the development of additional more potent selective androgen receptor modulators.
Interaction between ER␣, Tcf1, and Tcf4 was reported in a previous study, with Tcf4 inhibition of ER␣ activity in rat mammary cells (51) . Although Tcf4 repression of ER␣ transcriptional activity was not observed here, possibly reflecting cell type-specific ER␣ effects, the highly conserved structures of steroid hormone receptor DBDs certainly suggest that Tcf4 or other Tcf proteins may interact with additional steroid hormone or nuclear receptors. However, the ability of AR to interact directly with multiple components of the Wnt/␤-catenin-Tcf pathway (Tcf4, ␤-catenin, and Groucho/TLE proteins) indicates that extensive cross-talk with this pathway may be a particular feature of the AR. Significantly, a very recent study observed AR repression by Tcf4 mutants lacking the N-terminal ␤-catenin binding site and the HMG box, suggesting that direct or indirect AR interactions may be mediated by other domains of Tcf4 (43) . Efforts are underway to assess Tcf4 interaction with other steroid hormone receptors and to further define the roles of particular Tcf4 domains in mediating AR association.
Although competition for ␤-catenin or other coactivators or corepressors may contribute to cross-talk between AR and Tcf4, the data in this study suggest a direct cooperative protein-DNA binding model for the AR-Tcf4 interaction. In this model the direct AR-Tcf4 interaction (in conjunction with the architectural DNA-bending properties of the Tcf4 HMG domain) would stabilize weak sequence-specific AR and Tcf4 DNA binding interactions on the promoters or enhancers of particular genes. The AR⅐Tcf4 complex (containing two ␤-catenin binding sites and possibly two Groucho/TLE sites) would then serve as a potent transcriptional repressor in resting cells and a very sensitive target for ␤-catenin-mediated activation signals. This model is consistent with AR binding to a Tcf4 binding element in the c-myc gene and consistent with previous studies showing cooperative binding interactions between AR and other sequence-specific transcription factors (59, 60) . It also provides a mechanism by which Wnt/␤-catenin signals may contribute to androgen-dependent prostate development and carcinogenesis by stimulating the transcription of specific AR-regulated genes and predicts that a number of Wnt/␤-catenin target genes in prostate may be cooperatively regulated by AR and Tcf4.
